Latest Conference Articles

Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.

Early assessment from an Australian team of investigators is targeting a pathway linked to hemoglobin expression.

High levels of fetal hemoglobin have previously been linked to the mitigation of morbidity and mortality of sickle cell anemia.

Those without prior exposure to venetoclax experienced the most benefit.

In a poster presented at ACG, investigators find a new patch test could help patients who are not responding to PPI therapy.

A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.

Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.

A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.

RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.

New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

New AAO 2020 findings suggest even geographical differences could define retinal detachment risks among nearsighted patients.

In data presented at AAO, investigators find BI 836680 shows early signals of bioactivity.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

The study presented at AAO provides an update on previously shared 6-month data from earlier this year.

Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.

Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.

Longer studies are needed to determine the effectiveness and durability of CDI interventions.